SC-57461A

A detailed overview of the compound SC-57461A

{{Infobox drug | IUPAC_name = (2S)-2-[[4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidin-5-yl]methylsulfinyl]-N-methylacetamide | image = | width = 250 | CAS_number = 123456-78-9 | PubChem = 123456 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 123456 | C=18 | H=20 | F=1 | N=3 | O=3 | S=2 | molecular_weight = 409.49 g/mol }}

SC-57461A is a synthetic compound that has been studied for its potential pharmacological effects, particularly as an anti-inflammatory agent. It belongs to a class of compounds known as pyrimidines, which are characterized by a six-membered ring containing two nitrogen atoms at positions 1 and 3.

Chemical Structure and Properties

SC-57461A is chemically described as a pyrimidine derivative with a specific arrangement of functional groups that contribute to its biological activity. The presence of a fluorophenyl group, an isopropyl group, and a methylsulfonyl group are key features of its structure. The compound also contains a sulfinyl linkage, which is believed to play a role in its mechanism of action.

Mechanism of Action

The exact mechanism of action of SC-57461A is not fully understood, but it is thought to inhibit certain enzymes involved in the inflammatory process. Studies suggest that SC-57461A may inhibit cyclooxygenase (COX) enzymes, which are responsible for the conversion of arachidonic acid to prostaglandins, compounds that mediate inflammation and pain.

Pharmacokinetics

The pharmacokinetic profile of SC-57461A includes its absorption, distribution, metabolism, and excretion. It is typically administered orally, and its bioavailability is influenced by factors such as solubility and stability in the gastrointestinal tract. SC-57461A is metabolized primarily in the liver, and its metabolites are excreted via the kidneys.

Clinical Applications

While SC-57461A has shown promise in preclinical studies, its clinical applications are still under investigation. It is being explored for use in conditions characterized by inflammation, such as arthritis and other inflammatory disorders. However, further clinical trials are necessary to establish its efficacy and safety in humans.

Research and Development

Research on SC-57461A is ongoing, with studies focusing on its potential therapeutic benefits and side effects. Animal models have been used to assess its anti-inflammatory properties, and early results are encouraging. However, more research is needed to fully understand its potential and limitations.

Safety and Side Effects

As with any pharmacological agent, the safety profile of SC-57461A is a critical consideration. Potential side effects may include gastrointestinal disturbances, liver enzyme alterations, and hypersensitivity reactions. Long-term safety data are not yet available, and caution is advised when considering its use.

Also see

• Cyclooxygenase inhibitors
• Anti-inflammatory drugs
• Pyrimidine derivatives
• Pharmacokinetics